Abstract - 603255 Disclosed is the compound 2-(3-(cyclopropylmethyl)-2-oxo-imidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of the compound 2-(3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof optionally in combination with a therapeutic...

The invention relates to a combination which comprises a DPP-IV inhibitor which is (S)-1-[(3-hydroxy-1--adamantyl)amino]acetyl-2-cyano-pyrrolidine in free form or in acid addition salt form and metformin or a pharmaceutically acceptable salt thereof for simultaneous separate or sequential use in the prevention delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV) in particular diabetes more especially type 2 diabetes mellitus conditions of impaired glucose t...

FIELD: medicine pharmaceutics.SUBSTANCE: invention relates to medicine and pharmaceutical industry and deals with pharmaceutical composition which includes dipeptidyl peptidase IV (DPPIV) inhibitor preferably vildagliptin in amount from 1.5 to 20% and metformin in amount from 80 to 98.5%. Active ingredients constitute from 60 to 98% of composition. Cellulose or its derivatives in amount from 1 to 20% is used as binding agent. Also described is method of obtaining said composition.EFFECT: novel c...

A process for making an oral dosage form of a pharmaceutical composition comprising the steps of: (a) combining a therapeutic compound selected from the group consisting of metoclopramide and propantheline bromide

THIS INVENTION RELATES TO A FORMULATION COMPRISING A DIPEPTIDYLPEPTIDASE IV (DPP-IV) INHIBITOR PREFERABLY VILDAGLIPTIN AND METMORFIN TO TABLETS COMPRISING SUCH FORMULATIONS AND TO PROCESSES FOR THE PREPARATION THEREOF.